Description
Prevención de eventos esqueléticos en pacientes con metástasis óseas por tumores sólidos
HEMLIBRA® 150 mg/mL es un medicamento anticuerpo monoclonal cuyo principio activo es Emicizumab
Frasco ámpula con 70 mg de polvo para solución inyectable
COFEPRIS: 0365C2006
Contiene Óxido de Zinc
SALPIFAR DT 37.5/325MG - TAB 20 SC JOHNSONÿS DE RL DE CV Prevención de eventos esqueléticos enPRINCIPIO ACTIVO: TRAMADOL, PARACETAMOL
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
recommand products
